Inspire Medical Systems (INSP) to Release Quarterly Earnings on Wednesday

Inspire Medical Systems (NYSE:INSP) is expected to be posting its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.70 per share and revenue of $264.0190 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 5:00 PM ET.

Inspire Medical Systems Stock Up 0.3%

Shares of Inspire Medical Systems stock opened at $65.78 on Monday. The firm has a market cap of $1.91 billion, a PE ratio of 44.75, a P/E/G ratio of 6.63 and a beta of 0.74. Inspire Medical Systems has a twelve month low of $64.77 and a twelve month high of $197.75. The business has a 50-day moving average price of $99.89 and a 200 day moving average price of $92.73.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wells Fargo & Company cut their price objective on Inspire Medical Systems from $160.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, January 14th. Oppenheimer lowered shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a report on Thursday, January 22nd. JPMorgan Chase & Co. upped their price objective on shares of Inspire Medical Systems from $82.00 to $118.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th. Finally, Royal Bank Of Canada cut shares of Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $175.00 to $90.00 in a research note on Tuesday, January 27th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $133.47.

Insider Buying and Selling at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the transaction, the director directly owned 26,046 shares in the company, valued at approximately $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Daiwa Securities Group Inc. increased its position in Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after purchasing an additional 130 shares during the period. Blair William & Co. IL boosted its stake in shares of Inspire Medical Systems by 5.1% in the third quarter. Blair William & Co. IL now owns 4,865 shares of the company’s stock valued at $361,000 after buying an additional 234 shares in the last quarter. XTX Topco Ltd grew its holdings in Inspire Medical Systems by 4.3% during the third quarter. XTX Topco Ltd now owns 7,289 shares of the company’s stock worth $541,000 after acquiring an additional 300 shares during the period. BOKF NA grew its holdings in Inspire Medical Systems by 18.1% during the third quarter. BOKF NA now owns 2,043 shares of the company’s stock worth $152,000 after acquiring an additional 313 shares during the period. Finally, Alliancebernstein L.P. raised its position in Inspire Medical Systems by 5.4% in the third quarter. Alliancebernstein L.P. now owns 6,773 shares of the company’s stock worth $503,000 after acquiring an additional 346 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.